Users Stopping Slimming Medications Gain Back Pounds Far More Rapidly Than People Using Diet and Exercise

A recent study indicates that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle plans.

Research printed in a prominent health publication demonstrates that while overweight individuals can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.

"Individuals buying such medications must be cognizant of the danger of quick weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.

This pace of recovery suggests a return to pre-treatment weight within about a year and a half.

Analyzing Treatments

The study, which examined 37 of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.

Scientists point out that individuals who shed pounds through lifestyle changes alone usually have a slower creep back—around 0.1 kg a month—once they finish.

Explaining the Quick Regain

Nutrition scientists propose the way of the injections accounts for the heightened rebound.

These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Stopping of this medication leads to appetite is unsuppressed, making overeating a significant risk."

A Chronic Condition?

Medical guidelines recommend the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.

Many experts argue that, given the significant potential of relapse, the treatment is often long-term.

This view is echoed by drug manufacturers, who state that the findings "emphasize the persistent character of obesity," comparing it to managing conditions like high blood pressure.

Patient Experiences

People who have discontinued the medication explain a sudden return of hunger.

"It was like a switch activating and I was suddenly extremely hungry," described one woman.

The struggle is exacerbated if individuals have not developed permanent dietary or behavioural changes during treatment.

Growing Use

Recent estimates show that a significant number of people in the UK have tried these injections in the last 12 months, with desire remaining high.

• Use is higher among females than males.
• The middle-aged age group shows the highest usage rates.
• A large proportion access the drugs through private healthcare rather than the NHS.

Ultimately, experts caution that while the jabs are powerful tools for shedding pounds, they are not a permanent solution and long-term success relies on combined lifestyle support.